Go Pro
→ 10% yields… from a gold security? (From Golden Portfolio) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$16.03
+1.0%		$17.70
$15.02
▼
$40.47
$1.54B0.085,877 shs17,354 shs
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
$9.25
-1.4%		$3.95
$0.18
▼
$10.99
$352.15M-0.3116,977 shs2,336 shs
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
$22.85
$29.23
$2.87
▼
$38.33
$1.41B1.46627,520 shs618,186 shs
TRAX
First Tracks Biotherapeutics
$39.49
+1.3%		$41.63
$14.72
▼
$49.91
$1.41BN/A639,357 shs491 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
+5.31%-3.35%-6.71%-7.14%-59.18%
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
-0.78%-4.74%+153.29%+460.61%+1,040.57%
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
+1.15%-19.51%-25.86%-0.39%+696.17%
TRAX
First Tracks Biotherapeutics
+1.01%+3.78%-9.56%+119.29%+3,898,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$16.03
+1.0%		$17.70
$15.02
▼
$40.47
$1.54B0.085,877 shs17,354 shs
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
$9.25
-1.4%		$3.95
$0.18
▼
$10.99
$352.15M-0.3116,977 shs2,336 shs
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
$22.85
$29.23
$2.87
▼
$38.33
$1.41B1.46627,520 shs618,186 shs
TRAX
First Tracks Biotherapeutics
$39.49
+1.3%		$41.63
$14.72
▼
$49.91
$1.41BN/A639,357 shs491 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
+5.31%-3.35%-6.71%-7.14%-59.18%
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
-0.78%-4.74%+153.29%+460.61%+1,040.57%
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
+1.15%-19.51%-25.86%-0.39%+696.17%
TRAX
First Tracks Biotherapeutics
+1.01%+3.78%-9.56%+119.29%+3,898,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
3.20
Buy$46.43189.73% Upside
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
0.00
N/AN/AN/A
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
3.00
Buy$44.0092.56% Upside
TRAX
First Tracks Biotherapeutics
2.77
Moderate Buy$66.5568.52% Upside

Current Analyst Ratings Breakdown

Latest BFNH, AAPG, DMRA, and TRAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/18/2026
TRAX
First Tracks Biotherapeutics
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$65.00
9/18/2026
TRAX
First Tracks Biotherapeutics
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$65.00
9/16/2026
TRAX
First Tracks Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00
9/16/2026
TRAX
First Tracks Biotherapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
9/16/2026
TRAX
First Tracks Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00
9/16/2026
TRAX
First Tracks Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00
9/14/2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/3/2026
TRAX
First Tracks Biotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$57.00
8/24/2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/21/2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$48.00
8/18/2026
TRAX
First Tracks Biotherapeutics
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$83.00
(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$82.10M18.23N/AN/A$2.04 per share7.86
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/AN/AN/AN/A($0.02) per shareN/A
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/AN/AN/AN/A($110.11) per shareN/A
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
-$177.71MN/AN/A801.25N/AN/AN/AN/AN/A
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
-$1.29M$0.01925.93N/AN/AN/A-84.67%-16.36%N/A
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
-$209.84M-$3.37N/AN/AN/AN/A-176.39%-77.86%N/A
TRAX
First Tracks Biotherapeutics
N/A-$1.84N/AN/AN/AN/AN/AN/AN/A

Latest BFNH, AAPG, DMRA, and TRAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026H1 2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/A-$0.65N/A-$0.6450N/A$22.24 million
8/12/2026Q2 2026
TRAX
First Tracks Biotherapeutics
-$0.74-$0.95-$0.21-$0.95N/AN/A
8/10/2026Q2 2026
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/A$0.01N/A$0.01N/AN/A
8/10/2026Q2 2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
-$0.4470-$0.39+$0.0570-$0.39N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/A
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/AN/AN/AN/AN/A
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/AN/AN/AN/AN/A
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
1.09
1.22
1.18
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/A
25.41
25.41
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/A
19.73
19.73
TRAX
First Tracks Biotherapeutics
N/A
14.28
14.28

Institutional Ownership

CompanyInstitutional Ownership
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/A
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/A
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
14.20%
TRAX
First Tracks Biotherapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/A
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
39.54%
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
0.40%
TRAX
First Tracks Biotherapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
76793.40 millionN/AN/A
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
338.07 million23.02 millionNot Optionable
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
4061.74 million61.49 millionNo Data
TRAX
First Tracks Biotherapeutics
10435.73 millionN/AN/A

Recent News About These Companies

Tidal Investments LLC Makes New Investment in First Tracks Biotherapeutics $TRAX
September 22 at 3:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tidal-investments-llc-makes-new-investment-in-first-tracks-biotherapeutics-trax-2026-09-22/
First Tracks Biotherapeutics (NASDAQ:TRAX) Research Coverage Started at Guggenheim
September 19 at 2:38 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31032216
Evercore ISI Starts First Tracks Biotherapeutics (TRAX) at Outperform
September 18, 2026  |  streetinsider.comhttps://www.streetinsider.com/New+Coverage/Evercore+ISI+Starts+First+Tracks+Biotherapeutics+%28TRAX%29+at+Outperform/27077856.html
Guggenheim initiates coverage of First Tracks Biotherapeutics with buy
September 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/guggenheim-initiates-coverage-of-first-tracks-biotherapeutics-with-buy/ar-AA2cnIfO
First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Rating Upgraded by Guggenheim
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-first-tracks-biotherapeutics-nasdaq-trax-stock-rating-upgraded-by-guggenheim-2026-09-17/
Guggenheim Starts First Tracks Biotherapeutics (TRAX) at Buy,
September 16, 2026  |  streetinsider.comhttps://www.streetinsider.com/Analyst+Comments/Guggenheim+Starts+First+Tracks+Biotherapeutics+%28TRAX%29+at+Buy%2C/27066556.html
Why First Tracks Biotherapeutics, Inc.’s (TRAX) Stock Is Up 5.01%
September 14, 2026  |  aaii.comA
Wellington Management Group LLP Makes New $1.16 Million Investment in First Tracks Biotherapeutics $TRAX
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-makes-new-116-million-investment-in-first-tracks-biotherapeutics-trax-2026-09-12/
Opaleye Management Inc. Invests $1.31 Million in First Tracks Biotherapeutics $TRAX
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-opaleye-management-inc-invests-131-million-in-first-tracks-biotherapeutics-trax-2026-09-11/
J. Anthony Ware Sells 39,265 Shares of First Tracks Biotherapeutics (NASDAQ:TRAX) Stock
September 5, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-trax-insider-buying-and-selling-2026-09-05/
First Tracks Biotherapeutics (NASDAQ:TRAX) Downgraded to "Sell" Rating by Wall Street Zen
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-first-tracks-biotherapeutics-nasdaq-trax-downgraded-to-sell-rating-by-wall-street-zen-2026-09-05/
First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stock
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-first-tracks-biotherapeutics-nasdaq-trax-director-sells-175828670-in-stock-2026-09-04/
First Tracks Biotherapeutics' (TRAX) Buy Rating Reiterated at HC Wainwright
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-first-tracks-biotherapeutics-trax-buy-rating-reiterated-at-hc-wainwright-2026-09-03/
First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-first-tracks-biotherapeutics-nasdaq-trax-receives-consensus-recommendation-of-moderate-buy-from-brokerages-2026-08-31/
First Tracks Biotherapeutics Inc (TRAX)
August 30, 2026  |  de.investing.comhttps://de.investing.com/equities/first-tracks-biotherapeutics-financial-summary
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
August 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351693/0/en/first-tracks-biotherapeutics-announces-participation-in-september-investor-conferences.html
Analysts Offer Insights on NA Companies: Cerebras Systems, Inc. Class A (CBRS), CitroTech (CITR) and First Tracks Biotherapeutics Inc (TRAX)
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CBRS/pressreleases/3848972/analysts-offer-insights-on-na-companies-cerebras-systems-inc-class-a-cbrs-citrotech-citr-and-first-tracks-biotherapeutics-inc-trax/
Barclays Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX)
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3846416/barclays-sticks-to-its-buy-rating-for-first-tracks-biotherapeutics-inc-trax/
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
August 13, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61173753/first-tracks-biotherapeutics-analysts-increase-their-forecasts-after-q2-results
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/12/3344098/0/en/first-tracks-biotherapeutics-announces-second-quarter-2026-financial-results-and-provides-business-update.html
First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from Wells Fargo
July 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3518217/first-tracks-biotherapeutics-inc-trax-gets-a-buy-from-wells-fargo/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascentage Pharma Group International stock logo

Ascentage Pharma Group International NASDAQ:AAPG

$16.02 +0.17 (+1.04%)
As of 09:36 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

BioForce Nanosciences stock logo

BioForce Nanosciences OTCMKTS:BFNH

$9.25 -0.13 (-1.42%)
As of 09/21/2026 03:59 PM Eastern

BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online at www.bioforceeclipse.com, as well as through social media and telemarketing channels. BioForce Nanosciences Holdings, Inc. is based in Virginia Beach, Virginia.

Damora Therapeutics, Inc. Common Stock stock logo

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$22.85 0.00 (0.00%)
As of 09/21/2026 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

First Tracks Biotherapeutics NASDAQ:TRAX

$39.49 +0.50 (+1.28%)
As of 09:45 AM Eastern
This is a fair market value price provided by Massive. Learn more.

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas